Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02248805 |
|
Recruitment Status :
Completed
First Posted : September 25, 2014
Last Update Posted : February 8, 2022
|
Sponsor:
MacroGenics
Information provided by (Responsible Party):
MacroGenics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Carcinoma | Drug: MGD007 | Phase 1 |
This is an open-label, multi-center, Phase 1 dose-escalation study to define a MTD, describe preliminarily safety, and to assess PK, immunogenicity, and potential anti-tumor activity of MGD007 in patients with relapsed or refractory metastatic colorectal cancer.
In the initial phase of the study, two dose schedules will be assessed in dose escalation, once weekly and once every three weeks administration of single agent MGD007. Following the establishment of an MTD, additional patients will enroll in four separate dose expansion cohorts to further optimize the dose and schedule of MGD007 administration.
In all segments of the study, patients who benefit from MGD007 treatment and continue to meet eligibility may continue treatment in Cycles 2 and beyond.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 95 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma |
| Actual Study Start Date : | October 2014 |
| Actual Primary Completion Date : | July 2, 2018 |
| Actual Study Completion Date : | July 2, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Does Escalation Arm A
MGD007 treatment once weekly
|
Drug: MGD007
MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent. |
|
Experimental: Dose Escalation Arm B
MGD007 treatment once every 3 weeks
|
Drug: MGD007
MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent. |
|
Experimental: Dose Expansion Arm C
MGD007 once every 3 weeks for K-ras wild-type and mutant metastatic CRC
|
Drug: MGD007
MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent. |
|
Experimental: Dose Expansion Arms
MGD007 2, 3, 6, or 12 doses/cycle
|
Drug: MGD007
MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent. |
Primary Outcome Measures :
- Characterize dose limiting toxicity and establish a maximum tolerated dose and schedule [ Time Frame: Cycle 1 of a 6 week cycle ]Safety is based on evaluation of adverse events (AEs) and serious adverse events (SAEs) from the time of study drug administration through the End of Study visit. The MTD will be defined separately for both the weekly and every three week schedules of MGD007 administration, and will be determined as the highest dose level at which the incidence of DLT is < 33% during the first cycle of MGD007 treatment.
Secondary Outcome Measures :
- Characterize the PK and Immunogenicity of MGD007 [ Time Frame: Beginning of treatment through end of treatment, an expected duration of less than 12 months ]Serum concentrations of MGD007 will be monitored. PK modeling will be performed and an appropriate model will be selected to describe the data.
- Describe any evidence of anti-tumor activity [ Time Frame: Every 6 weeks until End of Study, an expected duration of less than 12 months ]Obtain regular radiographic and clinical evaluations to assess treatment response.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- For the dose escalation cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 2 prior standard treatment regimens or standard treatment was declined.
- For the dose expansion cohorts, histologically-proven metastatic colorectal adenocarcinoma that is refractory to 1 prior standard treatment regimen or standard therapy was declined.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Measurable disease
- Intolerance to at least 2 prior standard therapy regimens
- Acceptable laboratory parameters
- Adult (≥18 years old)
Exclusion Criteria:
- Known brain metastasis
- Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease)
- Prior history of allogeneic bone marrow, stem-cell, or solid organ transplantation
- Prior treatment with checkpoint inhibitors and other immunotherapy treatments, including anti-LAG-3, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies, if less than 5 half lives before study drug administration
- Prior history of Grade 3 or greater drug-related diarrhea/colitis during treatment with checkpoint inhibitors or other immunotherapy treatments.
- Treatment with any local or systemic anti-neoplastic therapy or any other investigational agent in the 4 weeks prior to study drug administration
- Require, at the time of study entry, treatment with steroids > 10 mg/day of oral prednisone (or equivalent), except topical use, steroid inhaler, nasal spray or ophthalmic solution
- History of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
- Second primary malignancy that has not been in remission for greater than 3 years, with the exception of non-melanoma skin cancer, cervical carcinoma in situ,or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score <6), or resected melanoma in situ.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02248805
Locations
| United States, Connecticut | |
| Yale University, Yale Cancer Center | |
| New Haven, Connecticut, United States | |
| United States, Florida | |
| H. Lee Moffitt Cancer Center & Research Institute, Inc | |
| Tampa, Florida, United States, 33612 | |
| United States, Maryland | |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | |
| Baltimore, Maryland, United States, 21205 | |
| United States, Massachusetts | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Dana Farber Cancer Institute | |
| Boston, Massachusetts, United States, 02215 | |
| United States, North Carolina | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| Carolina Biooncology Institute | |
| Huntersville, North Carolina, United States, 28078 | |
| United States, Oregon | |
| Providence Portland Medical Center | |
| Portland, Oregon, United States, 97213 | |
Sponsors and Collaborators
MacroGenics
| Responsible Party: | MacroGenics |
| ClinicalTrials.gov Identifier: | NCT02248805 |
| Other Study ID Numbers: |
CP-MGD007-01 |
| First Posted: | September 25, 2014 Key Record Dates |
| Last Update Posted: | February 8, 2022 |
| Last Verified: | February 2022 |
Keywords provided by MacroGenics:
|
colon cancer colorectal carcinoma stage IV colorectal cancer |
Additional relevant MeSH terms:
|
Carcinoma Colorectal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms |
Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases |